- Apollo Global Management (NYSE: APO) is in advanced talks to acquire medical device maker DePuy Synthes from Johnson & Johnson.
- The firm is also expanding its credit arm by agreeing to acquire US$5.5b in auto loans from Truist Financial.
- Both potential transactions would broaden Apollo's mix of healthcare exposure and consumer credit activity beyond its existing focus areas.
- The DePuy Synthes talks and the Truist auto loan deal are only part of the bigger Apollo Global Management story. Check out 2 warning signs that Apollo Global Management investors should know about.
Consider widening your watchlist to other companies in similar capital allocation and sector diversification stories through 38 profitable AI stocks that aren't just burning cash.
Apollo Global Management is a US based diversified financial group that allocates capital across credit, private equity, infrastructure, secondaries and real estate, so a move into a medical device platform and a large block of consumer auto loans fits within its broad investment toolkit. The firm’s size, with a market value of about US$74.4b, gives it scope to pursue large corporate carve outs while also scaling specialized lending portfolios.
3 things going right for Apollo Global Management that this headline doesn't cover.
What these DePuy Synthes and Truist deals signal for the Apollo Global Management Narrative
The potential DePuy Synthes acquisition and the US$5.5b Truist auto loan purchase both lean into Apollo Global Management's existing Narrative around scaling origination and broadening its platform, rather than changing it. A large medical device carve out would extend Apollo's reach into healthcare alongside the industrial renaissance theme, while the auto loans deepen its role as a credit and retirement solutions provider. This aligns with the Narrative catalyst that emphasizes increased origination across private assets and credit. It also sharpens the execution risk already highlighted: most challenges are internal, since integrating a major carve out and a sizeable consumer portfolio will test systems, funding, and risk controls.
See how these catalysts shape Apollo Global Management's path to a $158 fair value.
The unresolved issue is whether Apollo prices and funds these assets in a way that protects spread-related earnings in a competitive and regulated market. The clearest check on that will be upcoming quarterly disclosures that break out funding costs, credit performance on the Truist book, and any early commentary on DePuy Synthes integration plans if a deal is signed.
One question Apollo Global Management still has to answer
All the deal activity is only half the picture. The more interesting thread is where current analyst models think Apollo Global Management ends up a few years from now, and how different that outcome looks to today. See where analysts expect Apollo Global Management to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com